<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003217</url>
  </required_header>
  <id_info>
    <org_study_id>9517</org_study_id>
    <secondary_id>POG-9517</secondary_id>
    <secondary_id>CDR0000066078</secondary_id>
    <nct_id>NCT00003217</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Pilot Study of Dose Intensification of Methotrexate and Cyclophosphamide in Patients With Advanced-Stage (III/IV) Small Non-Cleaved Non-Hodgkins Lymphoma and B-Cell All- A Limited Institution Phase III Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining more than one drug may kill more cancer cells.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of
      methotrexate and cyclophosphamide in treating children who have stage III or stage IV
      non-Hodgkin's lymphoma or acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Evaluate the feasibility and toxicity of dose intensification of methotrexate
      and cyclophosphamide in patients with stage III or IV small, noncleaved cell non-Hodgkin's
      lymphoma or B cell acute lymphoblastic leukemia. II. Estimate the response rate and survival
      of these patients after this therapy.

      OUTLINE: This is a two-stage study. Patients will receive cytarabine either by continuous
      infusion (first stage) or bolus injection (second stage). Patients are stratified by disease
      (stage III non-Hodgkin's lymphoma (NHL) vs stage IV NHL vs stage B acute lymphoblastic
      leukemia). Therapy for all patients consists of alternating courses of &quot;A&quot; and &quot;B&quot;. Patients
      with stage III disease receive 4 courses of chemotherapy (ABAB) while those with stage IV
      disease and B cell acute lymphoblastic leukemia receive 6 chemotherapy courses (ABABAB).
      Course A - Induction: Patients receive intrathecal methotrexate (IT MTX) and intrathecal
      cytarabine (IT Ara-C) on days 1, 4, and 11. Dexamethasone is administered by IV or orally
      twice a day on days 1-5. Cyclophosphamide IV is administered every 12 hours on days 1-3.
      Doxorubicin IV is administered over 15 minutes beginning 12 hours after the beginning of the
      6th dose of cyclophosphamide (day 4). At the same time, vincristine IV is administered, then
      repeated on day 11. Patients begin filgrastim (granulocyte colony-stimulating factor; G-CSF)
      subcutaneously or IV over 30 minutes on day 5. Course B - Induction: The first 10 patients
      enrolled receive cytarabine by continuous infusion while the second 10 patients enrolled
      receive cytarabine by bolus IV. Patients begin treatment on day 18 and receive methotrexate
      IV over 24 hours plus IT MTX during hour 1. Dexamethasone is administered by IV or orally
      twice a day on days 1-5. After completing the 24 hour IV MTX infusion, patients begin
      cytarabine by continuous infusion over 48 hours or bolus IV every 12 hours for 4 doses.
      Patients receive G-CSF subcutaneously or IV over 30 minutes beginning on day 22. Patients are
      assessed for remission status before day 36. Course A - Consolidation: Patients receive
      dexamethasone IV or orally twice a day on days 1-5. IT MTX and IT Ara-C are administered on
      days 1 and 4. Cyclophosphamide is administered as during Induction, with vincristine IV and
      doxorubicin IV over 15 minutes 12 hours later. Vincristine repeats 1 week later. G-CSF
      administration begins on day 5. Course B - Consolidation: Therapy begins on day 22 with
      dexamethasone administered as previously. Methotrexate infusion and IT MTX are administered
      as in Course B - Induction, as is cytarabine (either as a continuous infusion or bolus IV).
      G-CSF is also administered as previously. Patients are followed monthly for the first 6
      months, every 2 months for the next 6 months, then every 6 months for 3 years, then annually
      thereafter.

      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 16 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Granulocyte Colony-Stimulating Factor</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>NSC #614629</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>NSC #26271</other_name>
    <other_name>IND #7089</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>NSC #63878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Decadron</other_name>
    <other_name>NSC #034521</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Adriamycin</other_name>
    <other_name>NSC #123127</other_name>
    <other_name>IND #7038</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>amethopterin</other_name>
    <other_name>NSC #740</other_name>
    <other_name>IND #4291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #67574</other_name>
    <other_name>IND #7161</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Cytologically proven small, noncleaved cell non-Hodgkin's
        lymphoma, Burkitt's lymphoma, non-Burkitt's lymphoma, or B cell acute lymphoblastic
        leukemia (B-ALL) Stage III or IV B-ALL - must have FAB L3 morphology and have been
        registered on POG-9400

        PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: HIV antibody positive allowed Not pregnant or lactating

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No
        prior chemotherapy Endocrine therapy: Prior emergency steroid therapy may be allowed
        Radiotherapy: Prior emergency radiotherapy may be allowed Surgery: Prior surgery allowed
        Other: No concurrent dexamethasone as an anti-emetic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy C. Griffin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cook Children's Medical Center - Fort Worth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital, Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York - Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Memorial Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73126-0307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-0721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2T 5C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 3, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2004</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

